Barry, OppHub America Desk · · Source: prnewswire-all
ADMA Biologics Class Action Deadline: August 10
* Investors with substantial losses in ADMA Biologics between August 9, 2024, and March 25, 2026, should review the lead plaintiff filing deadline of August 10, 2026. * Watch for potential developments in other biopharmaceutical sector investor actions, such as those concerning $WIX+WL and $CAPR+WL.
Based on reporting from prnewswire-all.
ADMA Biologics (ADMA) investors facing substantial losses have until August 10, 2026, to lead a class action lawsuit. Allegations include channel stuffing and an undisclosed related party transaction. The lawsuit covers securities traded between August 9, 2024, and March 25, 2026.
Market context for this story
As of: After HoursLoading quotes…
Informational only — not investment advice. Full markets →
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
$ADMAADMA Biologics
TradingView
Live chart & market data via TradingView · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/ADMA and related $WIX, $CAPR. Not investment advice.
### Money Play * Investors with substantial losses in $ADMA+WL Biologics between August 9, 2024, and March 25, 2026, should review the lead plaintiff filing deadline of August 10, 2026.
## Catalyst Analysis: Investor Class Action Deadline The lead plaintiff filing deadline for the $ADMA+WL Biologics (NASDAQ: $ADMA+WL) class action lawsuit is Monday, August 10, 2026. Purchasers or acquirers of $ADMA+WL securities between August 9, 2024, and March 25, 2026, are eligible to seek appointment as lead plaintiff. The lawsuit alleges violations of the Securities Exchange Act of 1934 by the company and its officers.
## Technical Analysis & Key Risk Watch
Key levels for (educational): R2 $33.05 · R1 $32.37 · last $32.04 · S1 $31.13 · S2 $30.41.
Allegations against $ADMA+WL Biologics include an undisclosed related party transaction, the use of channel stuffing to inflate revenues, and a lack of adequate internal controls. A report on March 24, 2026, claimed $ADMA+WL would have reported revenue declines without extended payment terms. Subsequent news on March 25, 2026, and a downgrade on March 26, 2026, impacted the stock price.
## Impact on Biopharmaceutical Sector Investors are reminded that the deadline to lead the class action is approaching. This legal development highlights potential risks associated with financial reporting and internal controls within the biopharmaceutical sector. Other related investor alerts have been issued for companies like Wix.com Ltd. ($WIX+WL) and Capricor Therapeutics ($CAPR+WL).
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: August 3, 2026 at 8:56 PM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
Biopharma Legal Risk
A company called ADMA Biologics is being sued by angry investors who claim the company misled them about its sales and financial health. People who lost money trading these shares have until August 10, 2026, to step forward and help lead the legal case.
What changed
A class action lawsuit filing deadline and fraud allegations were announced against ADMA Biologics.
Who wins / who loses
Plaintiff law firms and short-sellers benefit from the legal scrutiny, while current shareholders and the company suffer reputational and financial risk.
Time horizon
Think in terms of the next few weeks.
Confidence & best fit
medium confidence · Long-term investor
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $ADMAWatch — track, don’t rush
The main company being sued, so its stock price is likely to be jumpy and risky right now.
View $ADMA chart → · End-of-day delayed data
Peer
- $WIXWatch — track, don’t rush
Another stock sometimes watched in similar investor action contexts.
View $WIX chart → · End-of-day delayed data
- $CAPRWatch — track, don’t rush
A fellow drug-maker that investors also monitor for legal or market news.
View $CAPR chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Options are too unpredictable right now because of the lawsuit news. Beginners should skip options here entirely.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Review eligible brokerage account statements for trading activity between August 2024 and March 2026 to determine if a legal claim is applicable.
What would break this thesis
- Dismissal of the class action lawsuit by the court or a rapid, favorable settlement clearing the company of wrongdoing.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from prnewswire-all.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).